Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Explore this paper's citation graph
Summary
The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful.
- Type
- article
- Published
- 2012-12-06
- Cited by
- 1,217
- References
- 41
- Access
- Open access
- OpenAlex
- https://openalex.org/W2138862624
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:17225396
Keywords
Aliskiren, Type 2 diabetes, Medicine, Internal medicine, Diabetes mellitus
References
- A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis of general population cohorts
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
- Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
- The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
- Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials
- Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
- Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
- Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
- Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
- Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate
- Surrogate End Points in Clinical Trials: Are We Being Misled?
- Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
- Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
- Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
- Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study.
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Cited by
- ЛЕЧЕНИЕ ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ И МЕТАБОЛИЧЕСКИМ СИНДРОМОМ. МЕСТО КОМБИНИРОВАННЫХ ПРЕПАРАТОВ
- The amiloride-sensitive endothelial sodium channel and vascular tone.
- Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels.
- The population risks of dietary salt excess are exaggerated.
- Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms.
- Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
- The impact of regulatory action on the co‐prescribing of renin–angiotensin system blockers in UK primary care
- Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis
- Renin inhibition in heart failure and diabetes: the real story
- Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
- Blood pressure targets for hypertension in patients with type 2 diabetes.
- New antihypertensive medications and clinical implications.
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
- Diabetes und Nieren
- Minimize drug-induced hyperkalaemia by increasing awareness and using preventative strategies
- Consider specific co-morbidities and disease aetiology when treating hypertension in patients with chronic kidney disease
- Einfluss der doppelten RAAS-Blockade auf die Progression der Niereninsuffizienz bei diabetischer Nephropathie
- Hypertonie-Update 2014
- Proteinurie und Blocker des Renin-Angiotensin-Aldosteron-Systems
- Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease.
Related papers
- ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ
- चितलवाना पंचायत समिति में मानव गरीबी सूचकांक - 2016 ( à¤à¤• गà¥à¤°à¤¾à¤® सà¥à¤¤à¤°à¥€à¤¯ à¤à¥Œà¤—ोलिक अधà¥à¤¯à¤¯à¤¨ )
- DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION
- A GEOMETRIC MEAN IN THE FURUTA INEQUALITY